MR contrast agent developer Epix Medical has begun a multicenter phase IIa clinical trial of its MS-325 blood-pool contrast agent for imaging both the coronary arteries and myocardial perfusion.
The goal of the study is to assess the feasibility of using MS-325-enhanced MR angiography for coronary angiography and cardiac perfusion imaging, according to the Cambridge, MA-based firm.
By AuntMinnie.com staff writersJuly 12, 2004
Related Reading
Epix launches new MS-325 trial, July 8, 2004
Schering submits MS-325 for EU approval, June 7, 2004
Epix raises $96 million, June 4, 2004
Epix floats new debt, June 2, 2004
Copyright © 2004 AuntMinnie.com
